Author

Andrew Greenspan

Observed names: A Greenspan, A. Greenspan, A.R. Greenspan, Andrew R. Greenspan

Observed institutions: Emory University, Georgetown University, Georgetown University Medical Center, The US Oncology Network, Georgetown Lombardi Comprehensive Cancer Center, Janssen Scientific Affairs (United States)

OpenAlex ID: A5109071976

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 599

Antitumor Activity of Liposome-Encapsulated Doxorubicin in Advanced Breast Cancer: Phase II Study

1990 · J. Treat, A. Greenspan, et al. · JNCI Journal of the National Cancer Institute · 122

Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.

1989 · T R Spitzer, M Cottler-Fox, et al. · PubMed · 57

Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease.

1990 · A Greenspan, H J Deeg, et al. · PubMed · 36

775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study

2021 · Bruce E. Sands, Peter M. Irving, et al. · Gastroenterology · 31

The association of depo-medroxyprogesterone acetate and breast cancer

1980 · A.R. Greenspan, R.A. Hatcher, et al. · Contraception · 30

Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.

2019 · Roberto Pili, David I. Quinn, et al. · Journal of Clinical Oncology · 21

Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: Enhanced CD34+ cell collections are not necessarily cost-effective

1999 · Luke P. Akard, James M. Thompson, et al. · Transplantation and Cellular Therapy · 17

PDF

Impaired PBPC collection in patients with myeloma after high-dose melphalan

2004 · J. Jansen, J.M. Thompson, et al. · Cytotherapy · 13

Elliptinium: Phase II study in advanced measurable breast cancer

1989 · Joseph Treat, Andrew Greenspan, et al. · Investigational New Drugs · 7

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response

2010 · Robert M. Rifkin, Andrew Greenspan, et al. · Investigational New Drugs · 6

Peripheral Neuropathy and Low Dose Cisplatin

1988 · Andrew Greenspan, Joseph Treat · American Journal of Clinical Oncology · 6

Comment on “Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics”

2019 · Andrew Greenspan, Sharon Popik · Journal of the American Academy of Dermatology · 2

Membrane alterations by liposomes to enhance clinical efficacy of cytotoxic drugs.

1990 · A Rahman, L Dusre, et al. · PubMed · 1

Biodynamic response prediction in breast cancer patients receiving neoadjuvant chemotherapy.

2020 · Travis Morgan, Eric Whitacre, et al. · Journal of Clinical Oncology

Oncology comanagement agreements (CMA) and quality improvement.

2014 · David Haggstrom, Malaz Boustani, et al. · Journal of Clinical Oncology

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

2008 · Robert M. Rifkin, Gary Spitzer, et al. · Blood

Phase II trial of GM-CSF as maintenance therapy post–autologous peripheral blood stem cell transplantation in multiple myeloma

2005 · R.A. Mandanas, R. Beveridge, et al. · Transplantation and Cellular Therapy

PDF

Open-label, randomized comparison of dolasetron versus ondansetron for prevention of nausea and vomiting during high-dose chemotherapy and stem cell transplantation

2004 · R.A. Mandanas, R.A. Beveridge, et al. · Transplantation and Cellular Therapy

Researcher explains status of Depo Provera. [Answer to question of Marienetta Blackwell].

1981 · A Greenspan · PubMed

Works count: 20

Citation count: 948

H-index: 9

I10-index: 9